Fenobam

Fenobam is a selective and orally active mGluR5 antagonist (IC50=84 nM) that can penetrate the blood-brain barrier. Fenobam shows the Kd values of 54 nM and 31 nM on rat and human recombinant mGlu5 receptors, respectively. Fenobam has anxiolytic activity, inhibits self-administration behavior in mice, and induces apoptosis in cancer cells. Fenobam can be used for research on neurological diseases, cancer and drug addiction[1][2][3].

Product Specifications

CAS Number

[57653-26-6]

UNSPSC

12352005

Hazard Statement

H300, H315, H319, H335

Target

Apoptosis; mGluR

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fenobam.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=NC(CN1C)=O)NC2=CC=CC(Cl)=C2

Molecular Formula

C11H11ClN4O2

Molecular Weight

266.69

Precautions

H300, H315, H319, H335

References & Citations

[1]Porter RH, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther. 2005 Nov;315 (2) :711-21.|[2]Keck TM, et al. Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans. Psychopharmacology (Berl) . 2013;229 (2) :253-265.|[3]Liao S, et al. Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. PLoS One. 2017 Feb 23;12 (2) :e0171256.